POWERED BY

Gobia Enterprises invests in Bioelectrix to support development of bioelectronic wound healing technology

PublishedNovember 19, 2026

Gobia Enterprises has invested in Sweden’s Bioelectrix and joins the company as a new owner. As part of the investment, Jan Erik Smith of Gobia joins the company’s board, together with wound care clinical expert Tina Kjellén.

Earlier this year, Bioelectrix won the national Disruptor of the Year pitch competition at Innovation Night in Uppsala, taking the title and SEK 100,000 for its bioelectronic approach to chronic wound care.

Smiling woman holding flowers and an Innovation Night award as confetti falls on stage

The investment

Gobia Enterprises builds on the Smith family’s experience of developing ABIGO Medical into an international wound care business. The family has experience in bringing wound care products to market and expanding internationally. In addition to providing capital, Gobia will contribute strategic input on industry partnerships, intellectual property and future financing.

“Having previously been involved in building an international wound care business through ABIGO Medical, we have seen firsthand the challenges of treating difficult wounds. What particularly attracted us to Bioelectrix is its ambition to go beyond managing wounds and actively influence the biological healing process itself. We look forward to contributing our experience as the company advances towards clinical application.” – Jan Erik Smith, Gobia Enterprises

Board and team

Bioelectrix is led by co-founders Caroline Johansen (CEO) and José Leal (CTO). Co-founder Maria Asplund’s research at Chalmers University of Technology laid the scientific foundation for the company. The founders are first-time entrepreneurs and have focused on building the expertise needed to take a medical device from research to patients.

The board is chaired by Jan Hörling and includes Tina Kjellén, former clinical lead at woundEL, bringing clinical wound care experience to the board. Mattias Munnich of Chalmers Ventures and Henrik Claesson also contribute at board level. Jan Erik Smith adds experience in developing an international wound care business.

Together, the team covers bioelectronics, engineering, regulatory and quality, clinical wound care, finance and commercial experience from the wound care industry.

“With Jan Erik and Tina joining our board, we now have a complete team with the breadth of expertise to take Bioelectrix all the way to patients.” – Caroline Johansen, CEO and co-founder, Bioelectrix

With the investment and strengthened board in place, Bioelectrix is preparing for its next development stage. In 2027, the company will build stronger evidence of the treatment effect on human skin, complete its stimulation system and secure European patent protection. It will also deepen its dialogue with established wound care companies, drawing on Gobia’s industry experience.

These milestones are intended to lay the foundation for the company’s next financing round, planned for 2027, and its first clinical study in patients, where Tina Kjellén’s clinical experience will be central.

Bioelectrix’s long-term goal is to obtain CE marking around 2030, with the aim of making bioelectronic wound healing available to patients across Europe.

Bioelectrix Sweden AB is a Gothenburg-based medtech company developing a wearable electrode designed to restore the body’s natural electrical healing signal, helping chronic wounds close faster. The patent-pending technology originates from research at Chalmers University of Technology. In laboratory studies on human skin cells, wounds closed up to three times faster. Bioelectrix was founded in 2025 and is based at CoAx, Sahlgrenska Science Park.

Source